Hepatitis B nanoparticle-based vaccine for influenza virus
AssigneeThe United States of America, as represented by the Secretary, Department of Health and Human Services
InventorsAudray K. Harris, Dustin M. McCraw
Life of this patent
Estimating the term…
Abstract
Fusion proteins comprising one or more portions of hepatitis virus core antigen (HBcAg) fused to immunogenic portions of influenza virus hemagglutinin (HA) protein, and nanoparticles (virus-like particles) formed from such proteins, nucleic acid molecules encoding such proteins, methods of making such nanoparticles, methods of using the disclosed nanoparticles to vaccinate an individual against influenza virus, and antibodies elicited by vaccination of a mammal with the disclosed nanoparticles.
Claims23
A fusion protein comprising:
- a first fusion protein comprising an immunogenic peptide from helix A from the stem region of an influenza hemagglutinin (HA) protein joined to the carboxyl-terminal end of the α3 helix from a hepatitis B core antigen (HBcAg);
- and/or,
- a second fusion protein comprising an immunogenic peptide from helix A from the stem region of an influenza HA protein joined to the amino-terminal end of the α4 helix from a hepatitis B core antigen (HBcAg).
A nucleic acid molecule encoding a fusion protein comprising:
- a first fusion protein comprising an immunogenic peptide from helix A from the stem region of an influenza hemagglutinin (HA) protein, joined to the carboxyl-terminal end of the α3 helix from a hepatitis B core antigen (HBcAg);
- and/or,
- a second fusion protein comprising an immunogenic peptide from helix A from the stem region of an influenza HA protein, joined to the amino-terminal end of the α4 helix from a hepatitis B core antigen (HBcAg).
Dependencies are inferred from the claim text.